证券代码:301257 证券简称:普蕊斯 公告编号:2026—019 普蕊斯（上海）医药科技开发股份有限公司 关于董事会完成换届选举及聘任公司高级管理人员、证券事 3、职工代表董事：顾胜男女士 本次换届选举完成后，公司第四届董事会成员中兼任公司高级管理人员以及 由职工代表担任的董事人数总计未超过公司董事总数的二分之一，独立董事的人 数比例未低于公司董事会成员总数的三分之一，且包含一名会计专业人士，3 名 独立董事任职资格在公司 2026 年第一次临时股东会召开前已经深圳证券交易所 务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第三届董事 会任期于2026年3月15日届满，根据相关法律法规、规范性文件及《公司章程》 的有关规定，公司于2026年3月13日召开2026年第一次临时股东会，选举产生了 公司第四届董事会非独立董事、独立董事，与同日公司职工代表大会选举产生的 职工代表董事共同组成公司第四届董事会。 同日，公司召开第四届董事会第一次会议，选举产生了公司第四届董事会董 事长及各专门委员 ...

北京国枫（上海）律师事务所 关于普蕊斯（上海）医药科技开发股份有限公司 2026 年第一次临时股东会的法律意见书 国枫律股字［2026］B0002 号 致：普蕊斯（上海）医药科技开发股份有限公司（以下称"贵公司"或"普蕊斯"） 上海市黄浦区中山东二路 600 号 BFC 外滩金融中心 S2 栋 23 层 电话：021-23122000 传真：021-23122100 邮编：200010 北京国枫（上海）律师事务所（以下称"本所"）接受贵公司的委托，指派律师 出席并见证贵公司 2026 年第一次临时股东会（以下称"本次会议"）。 根据《中华人民共和国公司法》（以下称"《公司法》"）、《中华人民共和国 证券法》（以下称"《证券法》"）、中国证券监督管理委员会发布的《上市公司股 东会规则》（以下称"《股东会规则》"）、《律师事务所从事证券法律业务管理办 法》（以下称"《从业办法》"）、《律师事务所证券法律业务执业规则（试行）》 （以下称"《执业规则》"）及《普蕊斯（上海）医药科技开发股份有限公司章程》 （以下称"《公司章程》"）等有关规定，就本次会议的召集与召开程序、召集人资 格、出席会议人员资格、会议表决程序及表 ...

证券代码：301257 证券简称：普蕊斯 公告编号：2026-016 普蕊斯（上海）医药科技开发股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次会议采取现场表决与网络投票相结合的方式。 2、本次股东会不存在否决提案的情况。 3、本次股东会不涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 1、召开时间： （1）现场会议召开时间：2026 年 03 月 13 日（星期五）14:40 6、本次会议的召集、召开符合《公司法》《上市公司股东会规则》（以下 简称"《股东会规则》"）《深圳证券交易所创业板股票上市规则》等法律、行政 法规、部门规章、规范性文件和《公司章程》的有关规定。 7、会议出席情况 （1）股东出席的总体情况 参加本次股东会现场会议和网络投票表决的股东及股东代理人共 53 人，代 表股份 43,898,376 股，占公司有表决权股份总数的 55.5642%。 其中：通过现场投票的股东及股东代理人共 6 人，代表股份 31,826,983 股， 占公司有表决权股份总数的 40. ...

证券代码：301257 证券简称：普蕊斯 公告编号：2026-018 顾胜男女士当选公司职工代表董事后，公司第四届董事会兼任高级管理人员 以及由职工代表担任的董事人数总计未超过公司董事总数的二分之一，符合相关 法律法规、规范性文件及《公司章程》的规定。 特此公告。 普蕊斯（上海）医药科技开发股份有限公司董事会 2026 年 3 月 13 日 附件： 普蕊斯（上海）医药科技开发股份有限公司 关于选举公司第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第三届董事 会任期将于 2026 年 3 月 15 日届满，根据《中华人民共和国公司法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等法律法规、规范性文件及《公司章程》的有关 规定，公司按法定程序进行董事会换届选举。公司第四届董事会由 9 名董事组成， 其中包括职工代表董事 1 名。职工代表董事由公司职工代表大会选举产生。 公司于 2026 年 3 月 13 ...

一、董事会会议召开情况 普蕊斯（上海）医药科技开发股份有限公司（以下简称"公司"）第四届董事 会第一次会议于 2026 年 3 月 13 日在公司会议室以现场会议及通讯相结合的形式 召开。在公司 2026 年第一次临时股东会和职工代表大会选举产生第四届董事会 成员后，为保证董事会工作的衔接性和连贯性，经全体董事一致同意豁免本次会 议的提前通知时限，会议通知于当天以现场送达、电话、口头等方式向公司全体 董事传达。本次会议应出席董事 9 人，实际参与会议的董事 9 人，其中马林以通 讯方式出席会议，经全体董事共同推举，会议由董事赖春宝先生主持。公司高级 管理人员列席了本次会议。本次会议的召集、召开符合法律、法规、部门规章、 规范性文件和《公司章程》规定，会议合法有效。 证券代码:301257 证券简称:普蕊斯 公告编号:2026—017 普蕊斯（上海）医药科技开发股份有限公司 第四届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 经与会董事认真审议，一致同意通过如下决议： （一）审议通过《关于选举公司第四届董事会董 ...

Company Overview - Proris is a data-driven clinical research service provider focused on patient-centered approaches, creating a comprehensive project management system for clinical trials [1] - The company has established a nationwide network of clinical trial institutions, serving over 960 clinical trial institutions and covering more than 1,300 sites [2] - As of June 2025, Proris has undertaken over 4,200 international and domestic clinical projects, with 2,538 active projects [3] Industry Trends - In 2025, the number of drug clinical trials registered in China reached 5,173, a year-on-year increase of 6.44% [2] - The National Medical Products Administration approved 76 Class 1 innovative drugs, marking a 58% increase and a historical high [2] - China accounts for approximately 30% of the global pipeline of new drugs, ranking second worldwide [2] Financial Performance - Since its listing, Proris has distributed a total of CNY 46.1455 million in cash dividends to shareholders, emphasizing its commitment to shareholder returns [2] Competitive Advantages - The company has strong competitive advantages in various therapeutic areas, including hematologic tumors, thoracic tumors, digestive tumors, and rare diseases [3] - Proris is positioned as a key link between the research and clinical ends of the pharmaceutical innovation ecosystem, enhancing the efficiency and quality of new drug development in China [3] Quality Management - Proris has undergone 281 inspections by national and provincial authorities, 14 by the FDA, and 5 by the EMA, with no major findings reported [4] - The company has established a systematic quality management framework, including over 280 standard operating procedures (SOPs) to ensure compliance and quality [4] Recruitment and Training - The recruitment plan is based on existing and new project needs, with a focus on optimizing the recruitment structure to adapt to market demands and regulatory standards [5] - Proris emphasizes a robust training system to enhance employee skills and ensure high-quality service delivery [5]

证券代码：301257 证券简称：普蕊斯 公告编号：2026-015 普蕊斯（上海）医药科技开发股份有限公司 关于召开 2026 年第一次临时股东会提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《公司章程》的有关规定，经普蕊斯（上 海）医药科技开发股份有限公司（以下简称"公司"）第三届董事会第十七次会议 审议通过，拟于 2026 年 03 月 13 日（星期五）召开公司 2026 年第一次临时股东 会（以下简称"股东会"），现将本次股东会有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 3、会议召开的合法性、合规性：本次股东会的召集、召开符合《中华人民 共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市 公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、行政法规、部 门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 03 月 13 日（星期五）14:40； （2）网络投票时 ...

Investment Rating - The report maintains a "Positive" investment rating for the clinical CRO industry [2] Core Insights - The clinical CRO industry is expected to enter a new growth cycle driven by improved supply-demand dynamics, with significant increases in order volume and pricing anticipated [3][5] - The domestic clinical CRO market is projected to reach a scale of 95.56 billion RMB by 2030, with a compound annual growth rate (CAGR) of approximately 13% from 2024 to 2030 [3][31] - The report highlights the increasing recognition of China's clinical trial quality on a global scale, suggesting that leading domestic CROs may expand internationally alongside innovative drug business development (BD) [3][38] Demand Summary - The demand for clinical CRO services is closely linked to the progress of clinical trials, with a notable recovery in innovative drug financing observed in 2025, where the financing amount reached 14.684 billion USD, a year-on-year increase of approximately 127% [3][17] - The number of clinical IND approvals in China for 2025 was 2,703, reflecting a year-on-year growth of about 19%, indicating a resurgence in clinical trial activities [3][27] - The report notes that the number of early-phase clinical trials (I and II) has also increased significantly, with I phase trials up by 13% and II phase trials up by 42% in 2025 [3][27] Supply Summary - The clinical CRO industry is characterized by a highly fragmented competitive landscape, with the leading company, Tigermed, holding only 12.8% market share as of 2023 [4][44] - The report indicates that many smaller companies are exiting the market due to previous demand shortages, leading to a consolidation of market share among larger players [4][46] - The average number of clinical trials per CRO company has increased by 20.6% year-on-year, indicating a trend towards greater concentration in the industry [4][55] Performance Tracking - The report anticipates a recovery in order prices for clinical CROs, with new order prices beginning to rise in 2025 after a period of decline [5][6] - The revenue trends for clinical CRO companies are showing signs of stabilization, with expectations for improved profitability as order prices recover [5][6] - Leading companies are expected to see significant improvements in their profit margins as new order prices increase [5][6] Recommended Companies - **Tigermed**: A leading global clinical CRO with a projected revenue of 6.66-7.68 billion RMB for 2025, representing a year-on-year growth of about 9% [7] - **Norse**: A specialized clinical CRO with a broad business scope, showing a year-on-year revenue growth of 24.48% in Q3 2025 [7] - **Prasis**: A leading SMO in China, with a significant increase in new contracts, showing a year-on-year growth of 40.12% in 2025 [7] - **Bohui Pharma**: Focused on one-stop R&D outsourcing, with a strong order reserve and consistent growth in new orders [7]

Core Viewpoint - The pharmaceutical and biotechnology sector is expected to experience valuation recovery driven by policy and industry resonance in 2025, with the sector's PE (TTM) rising from 31x as of September 30, 2025, indicating a positive investment outlook [1][35]. Group 1: Market Review - The pharmaceutical sector's PE (TTM) has fluctuated between 21x and 53x since 2015, with an average of 33x, and has shown signs of recovery since Q1 2025 after hitting a low in September 2022 [1][11][45]. - The market capitalization of pharmaceutical stocks held by equity funds was 12.2% in Q2 2025, reflecting a 1.8 percentage point increase and indicating a recovery trend [12][49]. Group 2: Global Economic Context - The return to a rate-cutting environment globally, particularly with the Federal Reserve's rate cut in September 2025, is favorable for innovative assets, while global aging trends are driving increased healthcare spending [2][36][56]. - China's pharmaceutical innovation is gaining momentum, with expectations of capturing a larger share of the global pharmaceutical market, thus enhancing the competitiveness of the domestic industry [2][36]. Group 3: Investment Thesis - The investment strategy is framed around a three-stage clinical value model: 1. "0→1" technological breakthroughs in innovative drugs and devices, enhancing domestic capabilities [2][36]. 2. "1→10" clinical validation with high-quality domestic drugs accelerating overseas licensing [2][36]. 3. "10→100" efficiency in the Chinese pharmaceutical supply chain, with CXO companies achieving stable growth through cost advantages [2][36]. Group 4: Recommended Companies - Key companies recommended for investment include Innovent Biologics (H), Eifang Biologics (U), Tianshili, WuXi AppTec (A+H), Prasis, Mindray Medical, United Imaging Healthcare, and Weisi Medical [3][37].

Core Viewpoint - The company announced the convening of its third board meeting on February 25, 2026, to review and approve the election of the fourth board of directors, including both non-independent and independent director candidates [2] Group 1: Board Election - The company proposed the election of four non-independent director candidates: Lai Chunbao, Yang Hongwei, Lai Xiaolong, and Ma Lin [2] - The company also nominated three independent director candidates: Shi Zhanzhong, Gu Shaoyu, and Ji Daowei [2] - The term for the newly elected board members is expected to last three years, starting from the date of approval at the company's first extraordinary shareholders' meeting in 2026 [2]